Development and validation of a predictive model for chemotherapy-associated thrombosis. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Markedly elevated serum total N-terminal propeptide of type I collagen is a novel marker for the diagnosis and follow up of patients with POEMS syndrome.
Wang C, Zhou YL, Cai H, Cheng XQ, Zhang W, Kang WY et al. A new equation to estimate glomerular filtration rate. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. J Neurol Neurosurg Psychiatry 2006 77: 973–976. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Zagouri F, Kastritis E, Gavriatopoulou M, Sergentanis TN, Psaltopoulou T, Terpos E et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood 2011 117: 6445–6449.ĭ'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Li J, Zhang W, Jiao L, Duan MH, Guan HZ, Zhu WG et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Lancet 1996 347: 702.ĭ'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I.
#PROGNOSTIC STUDY SKIN#
Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome. Ye W, Wang C, Cai QQ, Cai H, Duan MH, Li H et al. Pulmonary hypertension in POEMS syndrome. Li J, Tian Z, Zheng HY, Zhang W, Duan MH, Liu YT et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Li J, Zhou DB, Huang Z, Jiao L, Duan MH, Zhang W et al. POEMS syndrome: definitions and long-term outcome. Am J Hematol 2014 89: 214–223.ĭispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR et al.
#PROGNOSTIC STUDY UPDATE#
POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. New advances in the diagnosis and treatment of POEMS syndrome. This nomogram could be a useful and convenient tool in clinical practice to evaluate individualized prognosis in patients with newly diagnosed POEMS syndrome. Concordance index calculation (0.727, 95% CI 0.601–0.853, P=0.018) and calibration curve plotting demonstrated its significant predictive and discriminatory capacity in the validation cohort. These factors were incorporated together to develop a prognostic nomogram. On the basis of a randomized sample splitting, we first identified four baseline clinical variables, including age >50 years (hazards ratio (HR) 4.07, 95% confidence interval (CI) 1.41–11.76, P=0.009), pulmonary hypertension (HR 3.99, 95% CI 1.44–11.04, P=0.008), pleural effusion (HR 3.81, 95% CI 1.23–11.79, P=0.02) and estimated glomerular filtration rate <30 ml/min/1.73 m 2 (HR 8.25, 95% CI 2.18–31.25, P=0.002), associated with inferior overall survival in the derivation cohort, with the use of multivariate Cox regression model. We retrospectively included 362 patients with newly diagnosed POEMS syndrome at our institute from 2000 to 2015. In its dozens of clinical features, those with independent prognostic value are still not well characterized. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) is a multisystem disorder with a good long-term prognosis.
0 kommentar(er)
